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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.024Objective: We sought to define patient characteristics, outcomes, and associated
factors after mitral valve replacement in children.
Methods: We included 104 children undergoing at least one mitral valve replace-
ment between 1980 and 2003 and reviewed clinical records. Competing-risks
methodology was used to determine time-related prevalence and associated risk
factors after initial mitral valve replacement for death and repeat replacement.
Results: The underlying mitral valve disease was congenital in 83%, rheumatic in
13%, Marfan syndrome in 3%, and isolated endocarditis in 1%, with 64% having
primarily regurgitation, 16% having stenosis, 20% having both, and 32% having
undergone previous valvotomy, valvuloplasty, or repair. There were 137 valve
replacements, with 26 patients having more than one. Valve prosthesis type was St
Jude Medical in 37%, Björk-Shiley in 25%, Carbomedics in 20%, Ionescu-Shiley in
10%, and other types in 8%. Both early and late complications were common.
Median age at the initial replacement was 5.9 years (range, birth to 19 years).
Competing-risks analysis predicted 19% to have died at 15 years after initial
replacement, with risk factors including noncongenital valve morphology, lower
weight, and longer duration of cardiopulmonary bypass. A repeat replacement was
predicted for 71%, with risk factors including the presence of multiple left-heart
obstructive lesions and Ionescu-Shiley valve prosthesis.
Conclusions: Mitral valve replacement might be necessary in children with ex-
tremely dysplastic valves and severe hemodynamic impairment or after failed
repair. However, with the appropriate selection of the prosthetic valve and reduction
of cardiopulmonary bypass time, surgeons might decrease mortality and increase
prosthesis longevity.
Mitral valve replacement (MVR) or systemic atrioventricularvalve replacement is associated with unique clinical and tech-nical difficulties in pediatric patients. Outcomes of MVR arewell documented,1-4 and a strong incentive exists to repairrather than replace the valve when possible. Patients under-going MVR within the first few years of life pose several
challenges, including the small size of the valve annulus, left atrium, and left
ventricle in relation to available prostheses, with subsequent potential for leaflet
entrapment, left ventricular outflow tract obstruction, and conduction block.4-6 Late
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anticoagulation, the need for subsequent prosthetic valve
replacement as the child outgrows the initial valve, and an
ongoing risk of endocarditis and arrhythmias.2,7-9 The pur-
pose of this study was to use competing-risks methodology
to examine time-related risk factors associated with the
mutually exclusive events of death and repeat replacement
in children after MVR.
Patients and Methods
Study Subjects
Patients with MVR performed between January 1980 and February
2003 were identified from computerized databases. Some patients
who were included had prior MVR, and these prior MVR episodes
were included in the study, some of which dated back to January
1973.
Data Collection and Measurements
The study was approved by the institutional research ethics board.
Data collected from medical record review included patient demo-
graphics, preoperative cardiac and noncardiac diagnoses, clinical
condition, previous procedures and complications, echocardio-
graphic and cardiac catheterization assessments and procedures,
operative data, and postoperative and follow-up clinical status,
including echocardiographic measurements.
Data Analysis
Data are described as frequencies, medians with ranges, and means
TABLE 1. Procedural characteristics at initial, and subse-
quent MVRs combined (n  137)
Variable N Missing Value
Age at MVR, y
(median and range)
137 0 7.4 (birth to 19)
Weight at MVR, kg
(median and range)
125 12 20 (2.8-73)
Duration of cardiopulmonary
bypass, min
119 18 154 75
Duration of aortic
crossclamping, min
110 27 97 50
Type of MV replacement 137 0
St Jude Medical 50 (37%)
Björk-Shiley 34 (25%)
Carbomedics 27 (20%)
Ionescu-Shiley 14 (10%)
Hancock 6 (4%)
Homograft 3 (2%)
Carpentier-Edwards 2 (1%)
Fascia lata 1 (1%)
Size of MV implant, mm 136 1 24 5
Size of implant per kg body
weight, mm/kg
(median and range)
124 13 1.2 (0.4-6.4)
MVR, Mitral valve replacement.with SDs. Where data are missing, the number of nonmissing
704 The Journal of Thoracic and Cardiovascular Surgery ● Novevalues is given. Both replaced valve failure with subsequent re-
placement and mortality were modeled as time-dependent events
by using both Kaplan-Meier estimates and parametric methods,
with the association with risk factors being explored in multivari-
able analysis with bootstrap bagging.10 Competing-risks analysis
was used in a manner previously reported.11 Post-MVR echocar-
diographic assessments of mean diastolic valve gradient and esti-
mated right ventricular systolic pressure were modeled, and risk
factors were sought by using mixed linear regression.
Results
Patient Characteristics
During the study period, 104 patients (52 male patients)
underwent an initial MVR. The underlying valve disease
was congenital in 86 patients, rheumatic in 14 patients
(including 1 patient with endocarditis), Marfan syndrome in
3 patients, and isolated endocarditis in 1 patient. Congenital
heart disease in 86 patients included atrioventricular septal
defect (AVSD) in 31 patients, multiple left-sided obstruc-
tive lesions in 17 patients, atrioventricular discordance with
Ebstein malformation in 16 patients, other cardiac lesions in
8 patients, and isolated mitral valve (MV) anomaly in 14
patients. Left-sided lesions included aortic coarctation in 11
patients, aortic valve stenosis or regurgitation in 29 patients,
and subaortic obstruction in 16 patients. Before MVR, pro-
cedures to address other cardiac lesions were performed in
60 patients. Associated syndromes in 17 patients included
Down syndrome in 9 patients, Marfan syndrome in 3 pa-
tients, Scheie syndrome in 2 patients, and William, Kart-
agener, and Treacher-Collins syndromes in 1 patient each.
The MV dysfunction was primarily regurgitation in 67
patients, stenosis in 17 patients, and both in 20 patients.
Other than repair of the AVSD, previous MV procedures
had been performed in 33 patients, followed by a second
procedure in 4 patients. Procedures included valvuloplasty
in 22 patients, valvotomy in 8 patients, and repair in 14
patients.
MVR
Of the 104 patients, during the study interval, 78 patients
had only 1 MVR (18 subsequently died), 20 patients had 2
MVRs (9 subsequently died), 5 patients had 3 MVRs, and 1
patient had 4 MVRs (all currently surviving) for a total of
137 MVR episodes. The characteristics at the MVR episode
are shown in Table 1. The distribution of ages at the initial
MVR was bimodal, with an early peak around the 25th
percentile of 1.4 years and a later smaller peak around the
75th percentile of 12.3 years. The age at initial MVR was
significantly younger in those with congenital heart disease
versus those with other pathologic conditions (P  .004),
although those with congenital heart disease predominated
throughout all ages. Total mortality for all patients regard-
less of subsequent procedures is shown in Figure 1. The
mber 2004
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Danalysis of early and late complications relates to the total
137 episodes of MVR.
Postoperative Clinical Course
There were 17 deaths within 30 days of MVR. Postoperative
complications included reoperation for bleeding in 13 (9%)
MVRs, severe sepsis in 8 (6%) MVRs, and arrhythmias
requiring medical therapy in 34 (25%) MVRs. Temporary
pacing was required for 4 (3%) MVRs, and permanent
pacemaker placement was required for 14 (10%) MVRs. A
paravalvular leak was present in 7 (5%) MVRs, with a
stroke occurring in 5 (3%) MVRs. A reoperation before
hospital discharge was performed after 26 (19%) MVRs,
including revision in 4 MVRs or replacement of the pros-
thesis in 3 MVRs.
Late Complications
There was also important late morbidity after the 117 MVRs
not complicated by death or subsequent MVR within 30 days
of MVR. There was an episode of important bleeding related
to anticoagulation with 6 (5%) MVRs, with 2 episodes of
embolism caused by thrombus and 3 with transient ischemic
attacks. There were an additional 6 (5%) permanent pacemaker
implantations. Late arrhythmias occurred with 16 (14%)
MVRs. There were 6 (5%) later episodes of endocarditis, 3
(3%) of valve thrombosis, and 17 (15%) of perivalvular leak.
Anticoagulation at latest follow-up assessment included war-
farin in 86 MVRs, aspirin in 15 MVRs, persantin in 9 MVRs,
and no anticoagulation in 7 MVRs. Only one patient with
underlying congenital heart disease had cardiac transplantation
Figure 1. Overall time-related survival. All patients began at the
time of initial MVR (n  104) and are censored at the time of the
last follow-up assessment. Solid lines represent parametric point
estimates, dashed lines enclose 70% confidence intervals, circles
with error bars represent nonparametric estimates, and numbers
in parentheses represent the number of patients at risk.at 9 years after a second MVR.
The Journal of ThoraciCompeting Risks for Death or Subsequent Prosthesis
Replacement After Initial MVR
The competing-risks analysis relates outcomes only after
the initial MVR for each of the 104 patients. During
follow-up of the 104 initial MVR episodes, 26 valves were
subsequently replaced, and 18 patients died without a fur-
ther MVR. The hazard function for time-related transition to
a second MVR was characterized by a very brief and steep
early hazard phase (4 early-phase events) and a prolonged
late hazard phase (22 late-phase events). The hazard func-
tion for time-related transition to death without a second
MVR was characterized by a very steep early hazard phase
only. The competing risks for the 2 events showed that after
15 years from initial MVR, 71% of valves had been re-
placed, 19% of patients had died without a further MVR,
and 10% were surviving without a further MVR (Figure 2).
Incremental risk factors each for early-phase death and for
late-phase subsequent replacement after initial MVR were
sought and are shown in Table 2. A stratified graph of valve
longevity by different types of initial prosthesis shows that
mechanical valves (St Jude Medical [St Jude Medical, Inc,
St Paul, Minn], Björk-Shiley [Shiley, Inc, Irvine, Calif], and
Carbomedics [Sulzer Carbomedics, Inc, Austin, Tex)] had
similar and better longevity than tissue valves (Ionescu-
Shiley [Shiley] and other tissue valves, Figure 3). From the
multivariable competing-risks analysis, predicted outcomes
for a patient with good characteristics, including weight at
initial MVR of 20 kg, underlying AVSD after repair, and a
cardiopulmonary bypass (CPB) time of 120 minutes with
placement of a mechanical valve prosthesis, would show a
6% chance of death with a second MVR, a 74% chance of
a second MVR, and a 20% chance of survival with the
Figure 2. Time-related survival to subsequent replacement of the
initial valve prosthesis stratified by initial prosthesis type. All
patients began at the time of initial MVR (n  104). Lines repre-
sent parametric point estimates.original prosthesis in place 15 years later. In contrast, for a
c and Cardiovascular Surgery ● Volume 128, Number 5 705
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obstructive lesions who undergoes placement of an Ionescu-
Shiley valve prosthesis with a prolonged CPB time of 480
minutes, predicted outcomes 15 years later would show a
96% chance of death without a second MVR and a 4%
chance of a second MVR with almost no chance of survival
with the original prosthesis in place.
A competing-risks analysis was performed for out-
comes for the 26 patients who had a second MVR. The
hazard function for time-related transition to another
subsequent MVR for 6 patients was characterized by a
constant hazard phase. The hazard function for time-
related transition to death without a further MVR for 9
TABLE 2. Incremental risk factors for time-related transitio
1. For death without subsequent MVR*
Lower patient weight at MVR (kg)†
Initial valve morphology other than congenital heart disease
Longer duration of cardiopulmonary bypass at MVR (min)‡
2. For survival to a subsequent MVR§
Presence of multiple left-heart obstructive anomalies
Ionescu-Shiley valve type
*Final multivariable model included a significant missing value marker va
†After inverse transformation.
‡After squared transformation.
§Risk factors were sought only for late-phase events because there were
Figure 3. Competing-risks analysis for subsequent replacement
of the initial replaced mitral valve or death. All patients began at
the time of initial MVR (n  104) and could transition to either
death or a subsequent replacement. Solid lines represent para-
metric point estimates, dashed lines enclose 70% confidence
intervals, and circles with error bars represent nonparametric
estimates. The proportion of patients (expressed as percentage of
total) in each of 3 categories at any given time after initial MVR
is shown. Numbers in parentheses represent the number of pa-
tients at risk.patients was characterized by a prolonged early hazard
706 The Journal of Thoracic and Cardiovascular Surgery ● Novephase. The competing risks for the 2 events showed that
after 10 years from the second MVR, 37% of valves had
been replaced, 42% of patients had died without further
MVR, and 21% of patients were surviving without fur-
ther MVR. For comparison, at 10 years after the initial
MVR, 49% of valves had been replaced, 19% of patients
had died, and 32% of patients were surviving without a
second MVR.
Factors Associated with Serial Echocardiographic
Measurements After MVR
Mean echocardiographic gradient across the replaced MV
was available after 54 MVRs, with a total of 256 measure-
ments performed up to a maximum interval of 11.7 years
(mean, 3.2 years). Significant independent factors associ-
ated with a higher mean gradient during follow-up included
an increased interval from MVR (increase of 0.76 mm Hg
per year; P  .001) and a smaller absolute size of the MV
implanted (increase of 0.40 mm Hg per 1 mm decrease in
diameter; P .001). After controlling for these 2 factors, no
other factor was significantly associated with follow-up
gradient, including the age and size of the patient, the
cardiac morphology, or the type of prosthesis that was
implanted.
Estimated right ventricular systolic pressure was avail-
able after 41 MVRs, with a total of 157 measurements
performed up to a maximum interval of 11.7 years (mean,
3.0 years). The only significant independent factor associ-
ated with a higher right ventricular systolic pressure during
follow-up was an increased interval from MVR (increase of
1.03 mm Hg per year; P  .002).
Discussion
This study reports a single institutional experience with MVR
in 104 pediatric patients. The results of the competing-risk
analysis provide valuable information regarding the time-
related risk of death without repeat replacement and valve
om initial MVR (n  104) to either death or a second MVR
Parameter estimate ( SE) P value Reliability (%)
9.93 2.78 .001 89
1.31 0.64 .04 51
0.000016 0.000004 .001 47
2.57 0.53 .001 81
1.42 0.56 .02 60
for weight.
few early-phase events.n fr
riablelongevity.
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Similar to our study, reported mortality in young children
with MV disease has been high, particularly for patients
undergoing MVR, with most of the deaths occurring early.
Kadoba and colleagues5 reported a 36% likelihood of death
in the first year of life and a 20% likelihood of late death.
Hospital mortality has significantly decreased in recent
years, ranging from 12% to 33%.1 High mortality has been
associated with a greater ratio of prosthetic valve size to
body weight. Ultimately, even the smallest available pros-
thetic valves are considered too large for placement in small
patients, resulting in higher mortality.2,3 Additional surgical
options for small patients include further attempts at valve
repair, abandonment of the left ventricle, and performance
of an atrial septectomy and Damus-Kaye-Stanzel–type
anastomosis or transplantation.12
We noted that initial valve morphology other than con-
genital heart disease was a risk for mortality. This group
included 14 patients with rheumatic heart disease (1 died),
1 with endocarditis (who died), and 3 with Marfan syn-
drome (2 died). The benefits of reconstructive surgery are
important for young patients with Marfan syndrome, who
usually have a higher risk of aortic dissection.13 Recent
reports suggest that MV reconstruction in the setting of
active or healed endocarditis is feasible, can be performed
with low operative mortality and morbidity, and should be
considered rather than MVR for mitral regurgitation caused
by endocarditis.14 A 15-year study of rheumatic heart dis-
ease showed that the mean age at hospitalization was 11 
3 years.15 In our study, data suggest that older and younger
patients might have different underlying diagnoses, with
higher-risk noncongenital valve disease more likely in ad-
olescents.
Longer duration of CPB was also identified as a risk
factor for death without a repeat MVR. Bypass time might
be acting as a proxy for disease complexity. All organ
systems could be adversely affected by CPB, primarily the
heart, lungs, brain, and kidneys. The risk of serious com-
plications depends on the age of the patient, how ill they are
at the time of the operation, and the complexity of the
operation to be performed. The mean CPB time for the
entire cohort was 154  75 minutes compared with 317 
113 minutes for patients who died without repeat MVR. In
8 of the 10 MVRs with the longest duration of bypass, there
were other operations being performed concomitantly, in-
cluding aortic valve replacement or reconstruction with the
Ross or Konno procedure, repair of the AVSD, bidirectional
cavopulmonary anastomosis, and Fontan procedure.
Prosthetic Valve Longevity
We identified 2 risk factors for decreased time to a repeat
MVR after initial MVR: (1) the presence of multiple left-
heart obstructive anomalies and (2) Ionescu-Shiley valve
The Journal of Thoracitype. Left-heart lesions included aortic coarctation, aortic
valve stenosis or regurgitation, and subaortic obstruction.
The presence of other left-heart anomalies might place an
added burden on the prosthetic valve, particularly if there is
associated aortic stenosis.
The choice of prosthetic valve type is still debated. In our
study the majority of patients (37%) underwent MVR with
a St Jude Medical prosthetic valve. The advantages of a
mechanical prosthesis include better hemodynamic flow
characteristics for valves that are small in size, with a lower
profile associated with less potential for left ventricular
outflow tract obstruction and longer durability.1,6,16 Antico-
agulation regimen remains a matter of concern for patients
with mechanical valves. We noted that 10% of patients
received Ionescu-Shiley valves, which was characterized as
a risk factor for reduced valve longevity. Zweng and asso-
ciates6 report that 4 of 10 patients with a bioprosthesis
underwent reoperation within 17 to 47 months of an
initial MVR. Although bioprosthetic valves do not re-
quire anticoagulation, they do have problems of limited
durability.1,4
The results of this study show that the need for multiple
MVR might increase mortality. The most significant in-
crease in mortality was seen after 2 operations. Of the 20
patients who had 2 MVRs, 9 died without a third MVR.
Five patients had 3 MVRs with no deaths, and 1 patient is
a current survivor after 4 MVRs. We also noted that patients
who required a subsequent MVR within 4 months of the
initial MVR had higher mortality. In addition, patients aged
less than 1 year at the time of their initial MVR were at high
risk for both early death and an early subsequent MVR
(with associated high mortality).
Late complications were common. Prosthetic valve
thrombosis and embolism are comparatively frequent com-
plications after valve replacement operations.7,17,18 Previ-
ous studies have reported rates of thromboembolism of
0.7% to 2% per year.1,4 Bacterial endocarditis and bleeding
after MVR were reported in previous studies.5,7,9,19,20
Echocardiography remains the mainstay of follow-up
assessment. We noted that significant independent factors
associated with higher mean echocardiographic diastolic
gradient during follow-up included an increasing interval
from MVR (gradient worsens in a linear manner with time)
and a smaller absolute size of the prosthesis implanted.
Matsuoka and coworkers21 noted that 3 children with
MVRs with a St Jude Medical prosthesis of 23 mm or
smaller had greater mean echocardiographic diastolic gra-
dients than those who received prostheses of 25 mm or
larger. We also noted that the only significant factor asso-
ciated with higher right ventricular systolic pressure during
follow-up was an increased interval from MVR (pressure
increases with time).
c and Cardiovascular Surgery ● Volume 128, Number 5 707
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The results of our study show that lower patient weight,
valve morphology other than congenital heart disease, and
longer duration of CPB at initial MVR are significant pre-
dictors of death without a repeat MVR. Furthermore, the
presence of multiple left-heart obstructive anomalies and
use of the Ionescu-Shiley or bioprosthetic valve types were
identified as significant risk factors for earlier repeat MVR.
Ultimately, valve replacement might be necessary in chil-
dren with extremely dysplastic valves and severe hemody-
namic impairment or after failed repair. However, with the
appropriate selection of the prosthetic valve and reduction
of CPB time, surgeons might decrease morbidity and mor-
tality in pediatric patients undergoing MVR.
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Discussion
Dr Vincent Tam (Fort Worth, Tex). MVR in children is a difficult
subject to study because even in a large-volume center such as
yours, few patients undergo MVR each year. In addition to the
small number of patients, there is a great variability in the under-
lying MV disease and associated cardiac disease; the patients’ ages
and sizes span the entire spectrum from newborn to young adults.
Your results demonstrate some expected findings but also some
unexpected findings as well. I have a few questions.
Your study encompassed a 23-year period. Have you analyzed
results, looked for any period differences, for example, comparing
the last decade with the previous 13 years?
Can you explain why the underlying valve pathology, other
than congenital, was identified as an incremental risk factor for
death, particularly because these seem to occur mostly in the older
and larger patients?
Why is the mortality after the second MVR higher despite
potentially larger patient size? Were there a number of second
MVRs during the same hospitalization as the initial MVR? In
conjunction with this question, why is the hazard function for
death without repeat MVR different for the initial MVR versus a
second MVR?
Given the model that you have, what would you recommend for
a 4-kg child with infantile Marfan syndrome and severe MV
regurgitation, which I did not repair very well 2 days ago? What
should I do?
Last, is there any role for a bioprosthetic MVR in the pediatric
population? What would the longevity and mortality be for a
bioprosthetic MVR in an 18-year-old woman?
I commend the authors for their efforts in studying this difficult
subject.
Dr Caldarone. Thank you for your kind comments. We agree
that the question of an era effect is appropriate. The year of
operation was entered into the analysis and did not come out as a
significant risk factor; however, that does not mean an era effect is
absent. As you pointed out, a small series looking at a diverse
population requires analysis of a large number of variables, and
therefore a small effect in any one variable might not be detected.
I would suspect there is an era effect, but we were unable to detect
one.
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a risk factor for death, I share with you some concern with the use
of a basket term encompassing a diverse group of diagnoses,
especially a negative basket term meaning all diagnoses of non-
congenital origin. This technique lumps together these diagnoses,
and in aggregate they became statistically significant, when in
isolation they did not. Once again, this underscores the problem
with a large number of variables and a small data set.
The noncongenital deaths were basically related to rheumatic
disease, endocarditis, Marfan syndrome, and Shone syndrome. In
fact, 3 of the deaths were quite late deaths at 4, 4, and 10 years
after the operation, respectively. Therefore, in terms of decision
making in a patient with noncongenital MV disease, I really do not
think that should necessarily sway your decision about whether to
implant a valve.
With regard to the deaths after a second MVR, you have very
nicely pointed out one of the problems with our analysis. Patients
who had a short interval from the first to the second MVR and then
subsequently died after the second MVR were not identified in the
analysis looking at the first MVR. These were censored events
because they recurred after a second MVR. That might be an
inappropriate way to deal with this statistically because a patient
who requires 2 MVRs in the same hospital admission clearly is not
the same as a patient showing up electively for a second MVR
years later. Therefore, your point in that respect is well taken.
With regard to the poor-risk patient you described, there is no
easy answer. Repair, repair, and replace when necessary is what
we all use as our decision making, and it seems appropriate in the
patient you described. I think attempts at persistent replacement
need to be tempered with the fact that a patient with poor physi-
ologic status as a result of multiple futile attempts at repair might
be worse off than just biting the bullet up front and replacing the
valve. Therefore, in short, I would say the patient should have one
trip to the operating room for attempted repair. If the patient
subsequently requires a return to the operating room, I would
advocate another attempt at repair, and if it does not look satis-
factory in the operating room, the valve should be replaced.
Finally, what is the ideal patient for a tissue prosthesis? AsThe Journal of ThoraciWe could run our model and see if that actually is true. Ideally, in
a female patient you would want to skip the childbearing age with
a bioprosthesis in place, and after childbearing age, you would
want to be able to have a mechanical prosthesis for the rest of her
life. Therefore, I would say that would be the ideal indication.
Dr Gerhard Ziemer (Tuebingen, Germany). I have 2 ques-
tions. Did you ever encounter any secondary tricuspid valve prob-
lems by distortion when you had to use valves in the 4 to 6 mm/kg
range, such as in neonates or young infants?
Also, do you have any clue why the Carbomedics valve turned
out to be better in your risk analysis? Has it something to do with
the design?
Dr Caldarone. Personally, I have not run into distortion of the
tricuspid valve from the MV prosthesis; however, I have run into
patients with pulmonary hypertension, which causes tricuspid in-
sufficiency and might require tricuspid repair at the time of MVR.
With regard to the Carbomedics valve, there were no statisti-
cally significant differences between the mechanical valve types.
Although on the survival curve it looked like there were differ-
ences, the differences were not statistically significant.
Dr Carlo Marcelletti (Palermo, Italy). I would like to ask
about the incidence of complete atrioventricular block in MVR in
the setting of partial or complete AVSD.
Dr Caldarone. It was 10% in the entire series and 15% in
patients with AVSDs.
Dr C. Troconis (Caracas, Venezuela). Is there any role for an
autologous tricuspid valve translocation from the tricuspid site for
the MVR and implanting a cryopreserved bioprosthetic valve in
the right side in the pediatric population?
Dr Caldarone. No, that was not done in this series.
Dr Ross M. Ungerleider (Portland, Ore). I assume that 5 kg
was the smallest patient in your series, and yet sometimes we see
patients who are smaller. Is there any role for the Ross II operation,
maybe with an aortic homograft and a small polytetrafluoroethyl-
ene tube? Have you tried any novel approaches like that?
Dr Caldarone. Personally, I have not. There were either 2 or
3 homograft replacements in the series, but because there were sopatients get older, I suspect the tissue prostheses will last longer. few, we could not really identify that as a risk factor or benefit.c and Cardiovascular Surgery ● Volume 128, Number 5 709
